ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer and Sangamo enter gene therapy deal

by Ryan Cross
January 8, 2018 | APPEARED IN VOLUME 96, ISSUE 2

Drug giant Pfizer will partner with Sangamo Therapeutics to develop a gene therapy for the neurodegenerative disorders amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The therapy will use a zinc finger protein to bind a region of mutant DNA implicated in familial versions of the diseases. When the zinc finger is present, a second protein attached to it shuts down expression of the disease-causing gene. Sangamo will receive $12 million up front and potential milestones of up to $150 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment